Clinical Response and Pattern of B cell Suppression with Single Low Dose Rituximab in Nephrology.
antibody-mediated rejection
clinical nephrology
frequently relapsing nephrotic syndrome
idiopathic membranous nephropathy
immunosuppression
kidney transplantation
nephrotic syndrome
steroid-dependent nephrotic syndrome
Journal
Kidney360
ISSN: 2641-7650
Titre abrégé: Kidney360
Pays: United States
ID NLM: 101766381
Informations de publication
Date de publication:
28 May 2020
28 May 2020
Historique:
received:
07
01
2020
accepted:
20
03
2020
entrez:
4
4
2022
pubmed:
2
4
2020
medline:
8
4
2022
Statut:
epublish
Résumé
There is no consensus regarding dose and frequency of rituximab in nephrology with extrapolation of doses used in treating lymphoproliferative disorders. There are no guidelines on targeting initial and subsequent doses on the basis of CD19 Initially, 100 mg rituximab was given to 42 adults with steroid-dependent nephrotic syndrome (SDNS) and frequently relapsing nephrotic syndrome (FRNS), idiopathic membranous nephropathy (MN), and high-immunologic-risk kidney transplantation. Absolute and percentage levels of CD19 B cells and clinical status were assessed at baseline, days 30, 90, and 180, and at 1 year. Subsequent doses of rituximab were on the basis of CD19 B cell reconstitution and clinical response. CD19 B cell percentage decreased from 16.3 ± 7.6 to 0.3 ± 0.3 ( Low-dose rituximab induces sustained depletion of CD19 B cells for up to 90 days. Its role in preventing relapses in SDNS, FRNS, MN, and rejection needs further study.
Sections du résumé
Background
UNASSIGNED
There is no consensus regarding dose and frequency of rituximab in nephrology with extrapolation of doses used in treating lymphoproliferative disorders. There are no guidelines on targeting initial and subsequent doses on the basis of CD19
Methods
UNASSIGNED
Initially, 100 mg rituximab was given to 42 adults with steroid-dependent nephrotic syndrome (SDNS) and frequently relapsing nephrotic syndrome (FRNS), idiopathic membranous nephropathy (MN), and high-immunologic-risk kidney transplantation. Absolute and percentage levels of CD19 B cells and clinical status were assessed at baseline, days 30, 90, and 180, and at 1 year. Subsequent doses of rituximab were on the basis of CD19 B cell reconstitution and clinical response.
Results
UNASSIGNED
CD19 B cell percentage decreased from 16.3 ± 7.6 to 0.3 ± 0.3 (
Conclusions
UNASSIGNED
Low-dose rituximab induces sustained depletion of CD19 B cells for up to 90 days. Its role in preventing relapses in SDNS, FRNS, MN, and rejection needs further study.
Identifiants
pubmed: 35369364
doi: 10.34067/KID.0000072020
pii: K3602020000007
pmc: PMC8809290
doi:
Substances chimiques
Steroids
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
359-367Informations de copyright
Copyright © 2020 by the American Society of Nephrology.
Déclaration de conflit d'intérêts
S. Alex, J. George, N. Gracious, S. Kumar, E. Thomas, and N. Vineetha have nothing to disclose.
Références
Reumatismo. 2009 Oct-Dec;61(4):306-8
pubmed: 20143007
Am J Kidney Dis. 2007 Jan;49(1):158-61
pubmed: 17185157
Arthritis Rheum. 2003 Feb;48(2):455-9
pubmed: 12571855
Clin J Am Soc Nephrol. 2010 Dec;5(12):2188-98
pubmed: 20705965
Transplantation. 2018 Jan;102(1):44-58
pubmed: 28614191
Clin J Am Soc Nephrol. 2009 Aug;4(8):1317-23
pubmed: 19578004
Nephrol Dial Transplant. 2013 Jan;28(1):106-11
pubmed: 22764193
Arthritis Rheum. 2006 Sep;54(9):2970-82
pubmed: 16947528
Neurology. 2007 Aug 14;69(7):704-6
pubmed: 17698796
Pediatr Nephrol. 2019 May;34(5):855-863
pubmed: 30564878
Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1122-1124
pubmed: 31340980
J Am Soc Nephrol. 2016 May;27(5):1517-33
pubmed: 26567246
N Engl J Med. 2008 Jul 17;359(3):242-51
pubmed: 18635429
Pediatr Nephrol. 2019 Feb;34(2):253-259
pubmed: 30109447
Clin J Am Soc Nephrol. 2006 Jul;1(4):738-48
pubmed: 17699281
Sci Rep. 2018 Oct 23;8(1):15629
pubmed: 30353021
Pediatr Nephrol. 2017 Nov;32(11):2071-2078
pubmed: 28664242
J Am Soc Nephrol. 2014 Apr;25(4):850-63
pubmed: 24480824
Ann Rheum Dis. 2018 Aug;77(8):1143-1149
pubmed: 29695500
Pediatr Nephrol. 2004 Jul;19(7):794-7
pubmed: 15071769
J Am Soc Nephrol. 2015 Sep;26(9):2259-66
pubmed: 25592855
Transl Androl Urol. 2019 Apr;8(2):126-133
pubmed: 31080772
Am J Transplant. 2013 Jun;13(6):1503-11
pubmed: 23570303
N Engl J Med. 2010 Jul 15;363(3):211-20
pubmed: 20647198
Kidney Int. 2013 Mar;83(3):511-6
pubmed: 23325085
J Am Soc Nephrol. 2015 Oct;26(10):2545-58
pubmed: 25804280
Clin Exp Nephrol. 2016 Feb;20(1):103-10
pubmed: 26138356
Kidney Int Rep. 2016 Sep 06;2(1):89-90
pubmed: 29142946
Clin Kidney J. 2018 Jul 24;12(2):224-231
pubmed: 30976400
Am J Transplant. 2015 Feb;15(2):407-16
pubmed: 25612493
Pediatr Nephrol. 2014 Aug;29(8):1461-4
pubmed: 24619426
N Engl J Med. 2008 Aug 7;359(6):613-26
pubmed: 18687642
J Am Soc Nephrol. 2016 Jun;27(6):1811-22
pubmed: 26567244
Clin Exp Immunol. 2015 Apr;180(1):11-8
pubmed: 25370437
J Clin Oncol. 1998 Aug;16(8):2825-33
pubmed: 9704735
Transplant Proc. 2014;46(2):445-8
pubmed: 24655984
Clin J Am Soc Nephrol. 2007 Sep;2(5):932-7
pubmed: 17702725
Arthritis Rheum. 2012 Apr;64(4):1215-26
pubmed: 22231479
Lancet. 2002 Sep 21;360(9337):923-4
pubmed: 12354476
Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1173-1182
pubmed: 31340979
J Am Soc Nephrol. 2017 Jan;28(1):348-358
pubmed: 27352623
Transplantation. 2002 Nov 15;74(9):1207-10
pubmed: 12451255
Autoimmun Rev. 2012 Jul;11(9):646-52
pubmed: 22146313
J Am Soc Nephrol. 2011 Aug;22(8):1543-50
pubmed: 21784898
Transplant Direct. 2019 Jul 25;5(8):e475
pubmed: 31576371
Sci Transl Med. 2011 Jun 1;3(85):85ra46
pubmed: 21632984
Transplantation. 2009 May 15;87(9):1325-9
pubmed: 19424032
Clin Rheumatol. 2019 Apr;38(4):1217-1223
pubmed: 30680533
N Engl J Med. 2010 Jul 15;363(3):221-32
pubmed: 20647199